ScripImmunology will be the therapeutic focus for Novartis in the second half of 2025 and next year, according to Shreeram Aradhye, president of development and chief medical officer, as a pair of pipeline
Pink SheetThe US Court of Appeals for the Federal Circuit denied a request to block MSN Laboratories from selling a generic version of Novartis ’ Entresto (sacubitril/valsartan) while a patent dispute is on
Pink SheetUS President Donald Trump appears to be giving the drug industry more time to voluntarily come up with ways to bring American drug prices more in line with those paid by other wealthy nations, a sign
In VivoPharma’s AI moment has arrived—not as a futuristic vision, but as a pragmatic engine of operational and scientific change. To understand how biopharma companies are navigating this shift, Define Ventu